Form 4: Evoke Pharma Director Todd C. Brady Acquires Stock Options
SEC Form 4
Director Todd C. Brady acquired stock options in Evoke Pharma, Inc. on May 22, 2024.
Summary
- On May 22, 2024, Todd C. Brady, a director of Evoke Pharma Inc., acquired stock options.
- The stock options grant Brady the right to buy 14,625 shares of common stock at an exercise price of $0.451 per share.
- These options vest on the one-year anniversary of the grant date, contingent upon Brady's continued service to Evoke Pharma.
- Following the transaction, Brady directly owns 14,625 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view this as a positive sign if they believe the director's interests are aligned with theirs.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option transaction |
| 05/24/2024 | Date of Form 4 filing |
| 05/21/2034 | Expiration date of the stock options |
Keywords
Evoke Pharma, Director, Stock Options, Beneficial Ownership, Form 4, Brady, EVOK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.